TY - JOUR
T1 - Preliminary findings of the effects of rivastigmine, an acetylcholinesterase inhibitor, on working memory in cocaine-dependent volunteers
AU - Mahoney, James J.
AU - Kalechstein, Ari D.
AU - Verrico, Christopher D.
AU - Arnoudse, Nicholas M.
AU - Shapiro, Benjamin A.
AU - De La Garza, Richard
N1 - Funding Information:
This work was conducted at, and supported by, the Michael E. DeBakey VA Medical Center, Houston, TX. Funding for this study was derived from a grant to RDLG ( DA023624 ) from the National Institute on Drug Abuse .
PY - 2014/4/3
Y1 - 2014/4/3
N2 - Long-term cocaine use is a risk factor for the onset of neurocognitive impairment. This study sought to determine whether the cholinesterase inhibitor rivastigmine could improve neurocognitive performance in cocaine-dependent individuals. Cocaine-dependent individuals who were not seeking treatment at the time of enrollment in the study were randomly assigned to receive placebo (n. = 16), rivastigmine 3. mg (n. = 13), or rivastigmine 6. mg (n. = 12). The baseline neurocognitive assessment, which included measures of attention/information processing (as measured by the Continuous Performance Task-II (CPT-II)), verbal learning/episodic memory (as measured by the Hopkins Verbal Learning Test-Revised (HVLT-R)), and working memory (as measured by the Dual N-Back Task), was conducted prior to the administration of study medication (Day 0). The follow-up assessment was conducted on Day 8 after the participants had received rivastigmine or placebo for 7. days (Day 2-8). Rivastigmine administration significantly improved performance on one measure of working memory span (mean n-back span). This study provides additional data showing that cocaine-associated neurocognitive impairment, specifically working memory deficits, can be remediated, at least to some degree.
AB - Long-term cocaine use is a risk factor for the onset of neurocognitive impairment. This study sought to determine whether the cholinesterase inhibitor rivastigmine could improve neurocognitive performance in cocaine-dependent individuals. Cocaine-dependent individuals who were not seeking treatment at the time of enrollment in the study were randomly assigned to receive placebo (n. = 16), rivastigmine 3. mg (n. = 13), or rivastigmine 6. mg (n. = 12). The baseline neurocognitive assessment, which included measures of attention/information processing (as measured by the Continuous Performance Task-II (CPT-II)), verbal learning/episodic memory (as measured by the Hopkins Verbal Learning Test-Revised (HVLT-R)), and working memory (as measured by the Dual N-Back Task), was conducted prior to the administration of study medication (Day 0). The follow-up assessment was conducted on Day 8 after the participants had received rivastigmine or placebo for 7. days (Day 2-8). Rivastigmine administration significantly improved performance on one measure of working memory span (mean n-back span). This study provides additional data showing that cocaine-associated neurocognitive impairment, specifically working memory deficits, can be remediated, at least to some degree.
KW - Acetylcholinesterase inhibitor
KW - Cocaine
KW - Neurocognition
KW - Rivastigmine
KW - Working memory
UR - http://www.scopus.com/inward/record.url?scp=84891653300&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84891653300&partnerID=8YFLogxK
U2 - 10.1016/j.pnpbp.2013.11.001
DO - 10.1016/j.pnpbp.2013.11.001
M3 - Article
C2 - 24239594
AN - SCOPUS:84891653300
SN - 0278-5846
VL - 50
SP - 137
EP - 142
JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry
JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry
ER -